At a Glance: Asthma Biologics
As featured in Asthma Care Complications from our September issue. Swipe through the images for product descriptions and links to prescribing information.Â
Swipe through the images for product descriptions and links to prescribing information.
Omalizumab (Xolair, Novartis/Genentech)
Initial U.S. approval: 2003
Indicated for: Moderate to severe persistent allergic asthma in patients 6 years of age or older not controlled by inhaled corticosteroids.
Contraindication: Severe hypersensitivity reaction to Xolair or any ingredient of Xolair.
Black Box Warning: risk of anaphylaxis.
Mepolizumab (Nucala, GSK)
Initial U.S. approval: 2015
Indicated for: Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Contraindications: History of hypersensitivity to mepolizumab or excipients in the formulation
Reslizumab (Cinqair, Teva)
Initial U.S. approval: 2016
Indicated for: Add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.
Contraindication: Known hypersensitivity toreslizumab or any of its excipients.
Black Box Warning: risk of anaphylaxis.
Dupilumab (Dupixent, Sonofi/Regeneron)
Initial U.S. approval: 2017
Indicated for: Add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma.
Contraindication: Known hypersensitivity to Dupixent or any of its excipients.
Benralizumab (Fasenra, AstraZeneca)
Initial U.S. approval: 2017
Indicated for: Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Contraindication: Known hypersensitivity to benralizumab or excipients.